Lanicemine

Source: Wikipedia, the free encyclopedia.
Lanicemine
Clinical data
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • (1S)-1-Phenyl-2-pyridin-2-ylethanamine
JSmol)
  • N[C@H](C1=CC=CC=C1)CC2=NC=CC=C2
  • InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1
  • Key:FWUQWDCOOWEXRY-ZDUSSCGKSA-N

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression.[1][2] Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.[3] However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.[4]

See also

References

  1. ^ "Lanicemine". AdisInsight. Retrieved 18 June 2017.
  2. PMID 26724279
    .
  3. PMID 23206319
    .
  4. ^ Flowers S. "Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of "momentum" for the company". Retrieved 6 February 2014.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lanicemine&oldid=1135092813"